NAV-240

Navigator Medicines, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NAV-240
Sponsor	Navigator Medicines, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults. (PHASE1)
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa (PHASE2)
Study of NAV-240 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NAV-240 CI brief — competitive landscape report
NAV-240 updates RSS · CI watch RSS
Navigator Medicines, Inc. portfolio CI